Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 18, 2013Annals of the Rheumatic DiseasesOpen Access

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDae‐Hyun YooHanyang University Seoul HospitalPHPaweł HrycajPoznan University of Medical SciencesPMPedro C. MirandaHospital Universitario de La Princesa

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yoo et al. (2013) studied this question.

synapsesocial.com/papers/6a704810f44fa9f079dddfdahttps://doi.org/10.1136/annrheumdis-2012-203090
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials2011 · 1,029 citations
  2. 2A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study2013 · 606 citations